I checked out this site for an explanation of the exclusivity...

I checked out this site for an explanation of the exclusivity period, as Jublia's ends at the end of April, as I observed above.

https://www.biopharmainstitute.com/faq/what-is-the-difference-between-drug-patents-and-drug-exclusivity#:~:text=Exclusivity%20periods%20typically%20last%20five,manufacture%20variants%20of%20the%20drug.

"Once the exclusivity period ends, other pharmaceutical companies can obtain technical information to manufacture variants of the drug. In some cases, the companies doing this have to pay a fee to the originator of the drug before doing so. In this way, the drug originator may get some revenue from the manufacturers of generic versions of their drugs."

So, hopefully that means we can start marketing our Eficonazole starting in May and Jublia's patent-holder just gets a cut...